Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA).
Nyxoah’s lead solution platform is based on the Genio® system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the world’s most common sleep disordered breathing condition that is associated with increased mortality risk* and comorbidities including cardiovascular diseases, depression and stroke.
Learn more about Genio, an alternative treatment for obstructive sleep apnea developed by Nyxoah for people who cannot tolerate, have failed or refused CPAP therapy.
